The innovation process in the pharmaceutical industry is, as for all evolutionary models of technological change, both ‘pushed by technology’ and ‘demand driven’. The core of the innovation relies on the research for new high value-added drugs to address unmet medical needs. To this end, tens of billions of dollars are invested per year in R&D. However, the decreasing number of approved drugs, which is accompanied by increasing R&D expenditures, demands alternative approaches to increase R&D productivity. This situation contributes to a revival of interest in peptides as potential tools and drug candidates.
28 June, 2011